{"a":[{"_":"Legend interim CEO talks rising competition as Carvykti maker posts first profit","$":{"href":"/pharma/legend-interim-ceo-stays-course-carvykti-maker-posts-first-profit-amid-rising-competition","hreflang":"en"}}]}

EarningsCarvyktiPositive

AI Analysis

Summary

Legend Biotech reported its first profitable quarter as Carvykti maker, with interim CEO Alan Bash addressing competitive pressures from T-cell engagers and Gilead's autologous CAR-T therapies.

Outcome Details

Legend Biotech posted its first profitable quarter

Importance:6/10

Sentiment:

0.30

earningsprofitabilityCAR-TcompetitionT-cell engagers

Related Companies

$LEGN

Read the original article

Published by FiercePharma on August 12, 2026 2:18 PM

Read Original